1.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596.
2.Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005;91(2):250-6.
3.Hendriks T, Said MA, Janssen LMA, van der Ende MY, van Veldhuisen DJ, Verweij N, et al. Effect of Systolic Blood Pressure on Left Ventricular Structure and Function: A Mendelian Randomization Study. Hypertension. 2019;74(4):826-32.
4.Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011:495349.
5.Mazzarotto F, Olivotto I, Boschi B, Girolami F, Poggesi C, Barton PJR, et al. Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing? J Am Heart Assoc. 2020;9(8):e015473.
6.Moreno C, Dumas P, Kaldunski ML, Tonellato PJ, Greene AS, Roman RJ, et al. Genomic map of cardiovascular phenotypes of hypertension in female Dahl S rats. Physiol Genomics. 2003;15(3):243-57.
7.van Rijn MJ, Schut AF, Aulchenko YS, Deinum J, Sayed-Tabatabaei FA, Yazdanpanah M, et al. Heritability of blood pressure traits and the genetic contribution to blood pressure variance explained by four blood-pressure-related genes. J Hypertens. 2007;25(3):565-70.
8.Li S, Pang Z, Zhang D, Duan H, von Bornemann Hjelmborg J, Tan Q, et al. Probing genetic overlap in the regulation of systolic and diastolic blood pressure in Danish and Chinese twins. Hypertens Res. 2014;37(10):954-9.
9.Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, et al. Animal Models of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2019;73(6):e87-e120.
10.Pravenec M, Křen V, Landa V, Mlejnek P, Musilová A, Šilhavý J, et al. Recent progress in the genetics of spontaneously hypertensive rats. Physiol Res. 2014;63(Suppl 1):S1-8.
11.Printz MP, Jirout M, Jaworski R, Alemayehu A, Kren V. Genetic Models in Applied Physiology. HXB/BXH rat recombinant inbred strain platform: a newly enhanced tool for cardiovascular, behavioral, and developmental genetics and genomics. J Appl Physiol (1985). 2003;94(6):2510-22.
12.Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, et al. Integrative analysis of gene expression, DNA methylation, physiological traits, and genetic variation in human skeletal muscle. Proc Natl Acad Sci U S A. 2019;116(22):10883-8.
13.Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014;157(1):77-94.
14.Saba LM, Hoffman PL, Homanics GE, Mahaffey S, Daulatabad SV, Janga SC, et al. A long non-coding RNA (Lrap) modulates brain gene expression and levels of alcohol consumption in rats. Genes Brain Behav. 2020:e12698.
15.Wang Y, Liu B. Circular RNA in Diseased Heart. Cells. 2020;9(5).
16.Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016;143(11):1838-47.
17.Sun C, Ni M, Song B, Cao L. Circulating Circular RNAs: Novel Biomarkers for Heart Failure. Front Pharmacol. 2020;11:560537.
18.Saar K, Beck A, Bihoreau MT, Birney E, Brocklebank D, Chen Y, et al. SNP and haplotype mapping for genetic analysis in the rat. Nat Genet. 2008;40(5):560-6.
19.Pravenec M, Gauguier D, Schott JJ, Buard J, Kren V, Bila V, et al. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. J Clin Invest. 1995;96(4):1973-8.
20.Sing CF, Stengård JH, Kardia SL. Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23(7):1190-6.
21.Nauta JF, Hummel YM, Tromp J, Ouwerkerk W, van der Meer P, Jin X, et al. Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. Eur J Heart Fail. 2020;22(7):1147-55.
22.Gomes CPC, Schroen B, Kuster GM, Robinson EL, Ford K, Squire IB, et al. Regulatory RNAs in Heart Failure. Circulation. 2020;141(4):313-28.
23.Verjans R, Derks WJA, Korn K, Sönnichsen B, van Leeuwen REW, Schroen B, et al. Functional Screening Identifies MicroRNAs as Multi-Cellular Regulators of Heart Failure. Sci Rep. 2019;9(1):6055.
24.Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharmacol Ther. 2018;187:31-44.
25.Wang L, Meng X, Li G, Zhou Q, Xiao J. Circular RNAs in Cardiovascular Diseases. Adv Exp Med Biol. 2018;1087:191-204.
26.Hirt MN, Werner T, Indenbirken D, Alawi M, Demin P, Kunze AC, et al. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J Mol Cell Cardiol. 2015;81:1-9.
27.Sodini SM, Kemper KE, Wray NR, Trzaskowski M. Comparison of Genotypic and Phenotypic Correlations: Cheverud's Conjecture in Humans. Genetics. 2018;209(3):941-8.
28.Ehret G. Measured and Genotyped Differences in Blood Pressure and the Usefulness of Precise Extreme Phenotypes Based on Cardiovascular Magnetic Resonance. Hypertension. 2019;74(4):747-8.
29.Li J, Kemp BA, Howell NL, Massey J, Mińczuk K, Huang Q, et al. Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy. J Am Heart Assoc. 2019;8(4):e010926.
30.Zhang D, Cao X, Li J, Zhao G. MiR-210 inhibits NF-κB signaling pathway by targeting DR6 in osteoarthritis. Sci Rep. 2015;5:12775.
31.Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation. 2012;19(3):215-23.
32.Kim JH, Park SG, Song SY, Kim JK, Sung JH. Reactive oxygen species-responsive miR-210 regulates proliferation and migration of adipose-derived stem cells via PTPN2. Cell Death Dis. 2013;4(4):e588.
33.Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 1998;431(3):351-6.
34.Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res. 2011;108(9):1122-32.
35.Mustapha S, Kirshner A, De Moissac D, Kirshenbaum LA. A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2000;279(3):H939-45.
36.Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, et al. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol. 2002;39(7):1229-35.
37.Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, et al. Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation. 2003;108(25):3075-8.
38.Regula KM, Baetz D, Kirshenbaum LA. Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes. Circulation. 2004;110(25):3795-802.
39.Buttrick P, Malhotra A, Factor S, Greenen D, Leinwand L, Scheuer J. Effect of aging and hypertension on myosin biochemistry and gene expression in the rat heart. Circ Res. 1991;68(3):645-52.
40.Dorn GW, 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res. 2009;81(3):465-73.
41.Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, et al. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet. 2008;40(5):546-52.
42.Wen J, Guan Z, Yu B, Guo J, Shi Y, Hu L. Circular RNA hsa_circ_0076906 competes with OGN for miR-1305 biding site to alleviate the progression of osteoporosis. Int J Biochem Cell Biol. 2020;122:105719.
43.Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11(3):241-7.
44.Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. Bioinformatics. 2003;19(7):889-90.
45.Team RC. R: A language and environment for statistical computing. Computing RFfS, editor. Vienna Austria2013.
46.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
47.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetJournal. 2011;17:10-2.
48.Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357-9.
49.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
50.Friedländer MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 2012;40(1):37-52.
51.Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.
52.Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64.
53.Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 1995;Series B (Mathodological)(57(1)):289-300.
54.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
55.Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biology. 2003;5(1):R1.
56.John B, Enright A, Aravin A, Tuschl T, Sander C, Marks D. Human MicroRNA Targets. PLoS Biol. 2004;2(11)(e363):1862-79.
57.Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
58.Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105.
59.Wang X. Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-ligation studies. Bioinformatics. 2016;32(9):1316-22.
60.Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019;20(5):1836-52.
61.Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42(17):e133.